×
It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.
If you have an existing eCom account, you can log in to the North American site using your current username and password.
Would you like to visit the North America page?
You can access the page here
If you have any questions, please feel free to contact our support team hytest@hytest.fi
As ST2 is a biomarker that is used for additive risk
stratification and prognosis of patients with heart failure (HF). In contrast
to BNP and NT-proBNP, ST2 is not affected by confounding factors such as age,
body mass index, and impaired renal function.
For the development of ST2 assays
we offer a
selection of monoclonal
antibodies and a recombinant antigen,
that can be used
as a standard.
ST2 is a member of the interleukin-1 receptor family, and it is also known as interleukin-1 receptor- like 1 (IL1RL-1). Unlike many other cardiac biomarkers, the levels of ST2 alter quickly in response to changes in the patient’s condition. This means that it helps physicians to take an appropriate course of action faster. Elevated levels of serum ST2 (sST2) in acute as well as chronic HF patients are strongly associated with the measures of HF severity, and they predict both recurrent hospitalization and mortality.
Measured levels of ST2 in chronic HF patients can be used for therapy evaluation and accordingly, decreased levels of sST2 that are responsive to medical treatment are associated with better outcomes for patients. The ST2 is an independent predictor of all-cause cardiac mortality, and it provides complementary prognostic information not only for NT-proBNP or BNP, but also for high-sensitivity cardiac troponin T (hs-cTnT) assays.
For the development of ST2 assays we offer a selection of monoclonal antibodies and a recombinant antigen, that can be used as a standard.
Learn more:
Copyright © Hytest Ltd.